Combined diphtheria-tetanus-pertussis vaccine for tetanus-prone wound management in adults

European Journal of Emergency Medicine

Volumn 13, Issue 2, 2006, Pages 67-71

  Hoel, Terje ^a   Wolter, Joanne M ^b   Schuerman, Lode M ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adults; Diphtheria tetanus acellular pertussis; Reduced antigen; Vaccination; Wound management

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; TETANUS TOXOID;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TETANUS; TREATMENT OUTCOME; VACCINATION; WOUND CARE; WOUND INFECTION;

ADULT; AGED; ANTIBODIES, BACTERIAL; CLOSTRIDIUM TETANI; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TETANUS; WOUND INFECTION;

EID: 33746611581     PISSN: 09699546     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mej.0000184993.51799.ad     Document Type: Article

References (28)

1. Hsu SS, Groleau G. Tetanus in the emergency department: a current review. Emerg Med 2001; 20:357-365.
2. Wassilak SF, Orenstein WA, Sutter RW. Tetanus toxoid. In: Plotkin SA, Mortimer EA, editors. Vaccines. 2nd ed. Philadelphia: WB Saunders Co.; 1994. pp. 57-90.
3. Center for Disease Control and Prevention (CDC). Recommendations and reports. Mrob Mortal Wkly Rep 2002; 51:1-35.
4. Advice of the High Council for Public Hygeine of France. Vaccine Schedule 2000 [In French]. Bulletin Epidemiologique Hebdomodaire 2000; 27:115-118.
5. Advisory Committee on vaccines of the Spanish Association of Pediatrics. Childhood Immunization schedule 2001-2002 [In Spanish]. Anal Espanol Pediatr 2001; 55:30-38.
6. Recommendations of the Standiry Committee on Vaccinations of the Robert Koch Institute [in German]. Epidemiologisch Bull 2002; 28.
7. Helwig H, Mertsola J, Harvey D, Nicolopoulos D, Schaack JC, Sedlak W. Childhood immunisation in the European Union. Eur J Pediatr 1998; 157:676-680.
8. WHO Expanded Programme on Immunization. Immunization schedules in theWHO European region, 1995. Wkly Epidemiol Rec 1995; 70:221-228.
9. Galazka A. The changing epidemiology in the vaccine era. J Infect Dis 2000; 181 (Suppl 1):S2-S9.
10. Campins-Marti M, Cheng H, Forsyth K. International Consensus Group on Pertussis Immunisation. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2002; 20:641-646.
11. Robbins J, Schneerson R, Trollfors B. Pertussis in developed countries. Lancet 2002; 360:657-658.
12. Hoey J. Pertussis in adults. Canadian Medical Association Journal 2003; 168:453-454.
13. Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2:744-750.
14. Crowcroft N, Britto J. Whooping cough: a continuing problem. Br Med J 2002; 324:1537-1538.
15. Guris D, Strebel P, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults 1990-1996. Clin Infect Dis 1999; 28:1230-1237.
16. He Q, Viljanen M, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunised population. J Am Med Assoc 1998; 280:635-637.
17. Keitel W, Edwards K. Pertussis in adolescents and adults: time to reimmunize. Semin Respir Infect 1995; 10:51-57.
18. Galazka A, Robertson S, Oblapenko G. Resurgence of diphtheria. Eur J Epidemiol 1995; 11:95-105.
19. Pachon I, Amela C, De Ory F. Age-specific seroprevalence of poliomyelitis, diphtheria and tetanus antibodies in Spain. Epidemiol Infect 2002; 129:535-541.
20. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-144.
21. Centers for Disease Control and Prevention (CDC). In: Atkinson W, Wolfe C, Humiston S, Nelson R (editors). Epidemiology and Prevention of vaccine-preventable diseases. 8th edition January 2005, Public Health Foundation Maryland. Chapter 6: Tetanus pages 66-67.
22. Porter JDH, Perkin MA, Corbel MJ, Farrington CP, Watkins JT, Begg NT. Lack of early antitoxin response to tetanus booster. Vaccine 1992; 10:334-336.
23. World Health Organisation. Proposed programme and budget 2000-2001. Vaccine-preventable diseases; http://www.wpro.who.int/public/policy/budget/ programme/38_vid.html
24. Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus- acellular pertussis vaccine in adults. Vaccine 2004; 22:305-308.
25. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21:2012-2023.
26. Van der Wielen M, Van Damme P, Joossens E, Francois G, Meurice F, Ramalho A. A randomized controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000; 18:2075-2082.
27. Turnbull F, Heath T, Jalaludin B, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000; 19:628-636.
28. Di-Pasquale A, Wolter J, Schuerman L. Management of pertussis in adolescents and adults: the role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. J Prevent Med Hygiene 2005; 46(1): 33-41.